**Appendix**

**Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego**

Mina Nikanjam, MD, PhD; Jose Tinajero, PharmD; Mary McGann, PharmD, BCOP; Jerry Li, PharmD; Jincheng Yang, PharmD; Felicity Shen, PharmD; Jason K. Sicklick, MD; Shumei Kato, MD; Edmund Capparelli, PharmD; Razelle Kurzrock, MD

This Appendix has not been edited and is provided as supplemental materials for this article, which was published in the *Journal of Hematology Oncology Pharmacy* in February 2023.

**Supplemental Figure 1:** Class of anti-cancer therapy administered in combination with drugs of interest. Safe and tolerable dose was one that was tolerated for at least one month with no clinically significant serious toxicities. Trametinib: A. Safe and Tolerable Dose or No Safe and Tolerable Dose, Everolimus: B. Safe and Tolerable Dose or No Safe or Tolerable Dose, Palbociclib: C. Safe and Tolerable Dose or No Safe or Tolerable Dose

**Supplemental** **Figure 1A:**

■ =Targeted ■ =Immunotherapy + Targeted

■ =Chemotherapy + Targeted ■ =Chemotherapy + Immunotherapy + Targeted

■ =Hormonal + Targeted ■ =Hormonal + Immunotherapy + Therapy

■ =Hormonal ■ =Chemotherapy + Hormonal + Immunotherapy + Targeted

■ =Immunotherapy ■ =Chemotherapy

**Supplemental Figure 1B:**

■ =Targeted ■ =Immunotherapy + Targeted

■ =Chemotherapy + Targeted ■ =Chemotherapy + Immunotherapy + Targeted

■ =Hormonal + Targeted ■ =Hormonal + Immunotherapy + Therapy

■ =Hormonal ■ =Chemotherapy + Hormonal + Immunotherapy + Targeted

■ =Immunotherapy ■ =Chemotherapy

**Supplemental Figure 1C**

■ =Targeted ■ =Immunotherapy + Targeted

■ =Chemotherapy + Targeted ■ =Chemotherapy + Immunotherapy + Targeted

■ =Hormonal + Targeted ■ =Hormonal + Immunotherapy + Therapy

■ =Hormonal ■ =Chemotherapy + Hormonal + Immunotherapy + Targeted

■ =Immunotherapy ■ =Chemotherapy

**Figure 1F**

**Supplemental Figure 2.** Number of drugs given in combination (including drug of interest): A. Trametinib, B. Everolimus, C. Palbociclib



**Supplemental Figure 2A**



**Supplemental Figure 2B**



**Supplemental Figure 2C**

**Supplemental Table 1. Anti-Cancer Drugs used in Combination with Trametinib**

|  |  |
| --- | --- |
| Anti-Cancer Drugs (N=105) | |
| Immune checkpoint inhibitors, N (%)  Pembrolizumab (Anti-PD1)  Nivolumab (Anti-PD1)  Ipilimumab (Anti-CTLA4) | 30 (28)  16  13  1 |
| Targeted therapy, N(%)  Bevacizumab (Anti-VEGF)  Palbociclib (CDK 4/6 Inhibitor)  Afatinib (EGFR Inhibitor)  Lenvatinib (VEGFR Inhibitor)  Erlotinib (EGFR Inhibitor)  Lapatinib (HER2/EGFR Inhibitor)  Pazopanib (VEGFR Inhibitor)  Sorafenib (BRAF/VEGFR Inhibitor)  Cetuximab (Anti-EGFR)  Everolimus (mTOR Inhibitor)  Panitumumab (Anti-EGFR)  Ruxolitinib (JAK Inhibitor)  Tamoxifen (SERM)  Cabozantinib (TKI Inhibitor)  Ixazomib (Proteasome Inhibitor) | 61 (58)  13  12  6  4  3  3  3  2  3  2  2  1  1  1  1 |
| Chemotherapy, N(%)  Carboplatin (Platinum Agent)  Etoposide (Topoisomerase Inhibitor)  FOLFIRI\*  Cisplatin (Platinum Agent)  Irinotecan (Topoisomerase Inhibitor) | 6 (6)  2  1  1  1  1 |
| Miscellaneous, N(%)  Sulindac (NSAID)  Metformin (Anti-Hyperglycemic) | 8 (7)  7  1 |
| Hormonal Therapy, N(%)  Letrozole (Aromatase Inhibitor) | 1 (1)  1 |

\*Drugs included in FOLFIRI are (Leucovorin, 5-Fluorouracil, Irinotecan)

**Supplemental Table 2. Anti-Cancer Drugs used in Combination with Everolimus**

|  |  |
| --- | --- |
| Anti-Cancer Drugs (N=71) | |
| Immune checkpoint inhibitors, N(%)  Pembrolizumab (Anti-PD1) | 2 (3)  2 |
| Targeted Therapy, N(%)  Lenvatinib (VEGFR Inhibitor)  Trastuzumab (Anti-HER2)  Bevacizumab (Anti-VEGF)  Lapatinib (HER2/EGFR Inhibitor)  Pazopanib (VEGFR Inhibitor)  Palbociclib (CDK 4/6 Inhibitor)  Abemaciclib (CDK 4/6 Inhibitor)  Erlotinib (EGFR Inhibitor)  Trametinib (MEK Inhibitor)  Cabozantinib (TKI Inhibitor)  Vismodegib (Hedgehog Inhibitor)  Copanlisib (PI3K Inhibitor)  Olaparib (PARP Inhibitor) | 41 (58)  8  8  4  4  3  3  2  2  2  2  1  1  1 |
| Chemotherapy, N(%)  Carboplatin (Platinum Agent)  Capecitabine (Pyrimidine Analog)  Vinorelbine (Vinca Alkaloid)  Etoposide PO (Topoisomerase Inhibitor)  Gemcitabine (Pyrimidine Analog)  Irinotecan (Topoisomerase Inhibitor)  Oxaliplatin (Platinum Agent)  Paclitaxel (Taxane) | 17 (24)  8  2  2  1  1  1  1  1 |
| Hormonal Therapy, N(%)  Exemestane (Aromatase Inhibitor)  Enzalutamide (Anti-Androgen)  Letrozole (Aromatase Inhibitor) | 8 (11)  4  2  2 |
| Miscellaneous, N(%)  Sulindac (NSAID)  Metformin (Anti-Hyperglycemic) | 3 (4)  2  1 |

**Supplemental Table 3. Anti-Cancer Drugs used in Combination with Palbociclib**

|  |  |
| --- | --- |
| Anti-Cancer Drugs (N=66) | |
| Immune checkpoint inhibitors, N(%)  Nivolumab (Anti-PD1)  Pembrolizumab (Anti-PD1) | 10 (15)  7  3 |
| Targeted Therapy  Trametinib (MEK Inhibitor)  Bevacizumab (Anti-VEGF)  Lenvatinib (VEGFR Inhibitor)  Cetuximab (Anti-EGFR)  Anakinra (IL-1 Inhibitor)  Everolimus (mTOR Inhibitor)  Afatinib (EGFR Inhibitor)  Dabrafenib (BRAF Inhibitor)  Ibrutinib (BTK Inhibitor)  Lapatinib (HER2/EGFR Inhibitor)  Olaparib (PARP Inhibitor)  Osimertinib (EGFR Inhibitor)  Ramucirumab (VEGF Inhibitor)  Temsirolimus (mTOR Inhibitor)  Trastuzumab (Anti-HER2) | 49 (74)  16  7  7  4  3  2  1  1  1  1  1  1  1  1  1 |
| Hormonal Therapy, N(%)  Anastrazole (Aromatase Inhibitor) | 1 (2)  1 |
| Miscellaneous, N(%)  Sulindac (NSAID)  Celecoxib (COX-2 Inhibitor)  Metformin (Anti-Hyperglycemic)  Nelfinavir (HIV Protease Inhibitor) | 6 (9)  4  1  1  1 |